Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The science behind Perspective Therapeutics’ Pb-212 alpha therapies is as advanced as its SEC disclosures are dense. Clinical trial readouts, isotope supply agreements and cash-runway forecasts are scattered across 300-page documents, leaving investors hunting for the numbers that matter. Whether you are searching for “Perspective Therapeutics insider trading Form 4 transactions” or trying to decode the latest “Perspective Therapeutics quarterly earnings report 10-Q filing,” the challenge is the same: translating technical oncology language into clear investment signals.
Stock Titan solves this problem by layering AI summaries, expert tagging and real-time EDGAR feeds onto every Perspective Therapeutics filing. Ask naturally—“understanding Perspective Therapeutics SEC documents with AI” or “Perspective Therapeutics 8-K material events explained”—and the platform surfaces concise answers. Our tools link each disclosure to its form type, so you can move from a “Perspective Therapeutics annual report 10-K simplified” overview to drill-downs on segment R&D spend, or jump straight to “Perspective Therapeutics Form 4 insider transactions real-time” for alerts when executives trade shares. Quarterly calls approaching? The “Perspective Therapeutics earnings report filing analysis” module highlights trial-cost trends before the market reacts.
Practical insight is our focus. Use insider dashboards to trace “Perspective Therapeutics executive stock transactions Form 4,” monitor dilution risk via shelf-registration statements, or check the “Perspective Therapeutics proxy statement executive compensation” section to evaluate incentive alignment with Pb-212 milestones. Every document—10-K, 10-Q, 8-K, S-3, DEF 14A—is indexed, time-stamped and cross-linked, giving you comprehensive coverage without combing through technical appendices. Complex biotech filings, explained simply; real-time intelligence, delivered the moment it matters.
Perspective Therapeutics, Inc. reported that it updated its corporate presentation on December 1, 2025. The new version is being made available to the market as an exhibit to a current report, giving investors and other stakeholders refreshed information about the company’s business and strategy. The company’s common stock continues to trade on the NYSE American under the symbol CATX.
Perspective Therapeutics, Inc. (CATX)11/13/2025, the officer acquired 11,000 shares of common stock in an open market transaction coded “P” for purchase. The weighted average price paid was $2.0268 per share, with individual trades executed in a range from $2.0235 to $2.0300. Following this transaction, the officer beneficially owns 59,800 shares of Perspective Therapeutics common stock held directly.
Perspective Therapeutics (CATX) director Robert F. Williamson, III reported a Form 4 purchase of common stock. On 11/12/2025, he bought 9,498 shares (transaction code P) at $2.10 per share.
Following the transaction, the filing shows 9,864 shares held indirectly via the RFW3 Revocable Trust and 108,982 shares held directly. This reflects insider open-market buying and updates his reported holdings.
Perspective Therapeutics (CATX) reported Q3 2025 results showing continued investment in its radiopharmaceutical pipeline. The company recorded a net loss of $25.969 million (loss per share $0.35) on $209 thousand of grant revenue. Operating expenses were driven by R&D of $20.339 million and G&A of $7.731 million, resulting in an operating loss of $27.861 million.
Liquidity remains solid with $174.1 million in cash, cash equivalents and short‑term investments as of September 30, 2025, which the company believes will fund current plans into late 2026. Year‑to‑date, operating cash outflows were $57.827 million, partially offset by $12.691 million from investing activities and $10.318 million from financing, including $9.986 million raised via the at‑the‑market program in February 2025.
Common shares outstanding were 74,337,990 as of November 6, 2025. The company continues Phase 1/2a work across VMT‑α‑NET, VMT01 and PSV359 while building out manufacturing capacity to support clinical and future commercial supply.
Perspective Therapeutics (CATX) furnished a press release announcing its financial results for the quarter ended September 30, 2025, and provided recent business highlights. The company also posted an updated corporate presentation on its website.
The press release was furnished as Exhibit 99.1 under Item 2.02, and the corporate presentation was filed as Exhibit 99.2 under Item 8.01. The Item 2.02 information is expressly not deemed “filed” under Section 18 of the Exchange Act.
FMR LLCPerspective Therapeutics (CATX). The filing shows beneficial ownership of 6,063,330 shares of common stock, representing 8.2% of the class, with a date of event of 10/31/2025.
FMR reports sole voting power over 6,057,277 shares and sole dispositive power over 6,063,330 shares, with no shared voting or dispositive power. Abigail P. Johnson is also a reporting person with beneficial ownership of 6,063,330 shares (8.2%) via dispositive power.
The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control. The filing notes that one or more other persons may have rights to dividends or sale proceeds, and that no single such person has an interest exceeding 5% of the class.
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics (CATX) amended and restated employment agreements for its CEO Johan (Thijs) Spoor, Chief Accounting Officer Jonathan Hunt, and Chief Medical Officer Dr. Markus Puhlmann. The updates reflect current base salaries and revise change-in-control provisions.
Base salaries are $680,000 for Mr. Spoor, $451,500 for Mr. Hunt, and $516,700 for Dr. Puhlmann. If employment ends without cause or for good reason during the three months before or 12 months after a change in control, severance includes salary continuation for 12 months (18 months for Mr. Spoor), a pro‑rated target bonus, an additional amount equal to the target bonus (1.5x target for Mr. Spoor), and COBRA premiums for up to 12 months (18 months for Mr. Spoor).
Equity awards subject to time-based vesting accelerate to full vesting, and performance-based awards vest at target upon qualifying terminations in the protection period or if awards are not assumed, replaced, or continued at closing, subject to a release of claims. Other existing terms remain in effect.
Perspective Therapeutics (CATX) filed an 8‑K announcing a press release and presentation with updated interim results from its Phase 1/2a study of [212Pb]VMT‑α‑NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors. The data are being presented at ESMO 2025 in Berlin. The materials also include the Company’s estimated cash, cash equivalents and short‑term investments as of September 30, 2025, which are preliminary, unaudited, and subject to change.
FAQ
What is the current stock price of Perspective Therapeutics (CATX)?
What is the market cap of Perspective Therapeutics (CATX)?
